CNMD, US2074101013

CONMED stock trades at EUR 41.30 ahead of results

Published on 10/05/2026 at 08:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CONMED stock costs EUR 41.30 on October 5, 2026, plus 0.24 percent versus EUR 41.20. Third-quarter results are due October 28, 2026.

CNMD, US2074101013, Illustration mit AI erstellt.

CONMED stock (ISIN US2074101013) was trading at EUR 41.30 at Lang & Schwarz on October 5, 2026 at 7:59 a.m. CEST, with a plus 0.24 percent change versus the prior close of EUR 41.20. According to Business Wire on October 1, 2026, CONMED will report third-quarter 2026 results after the market close on October 28, 2026.

Second-quarter revenue held steady

According to Zacks on July 30, 2026, second-quarter revenue increased 0.30 percent year over year to USD 343.50 million. Adjusted earnings per share rose 20.00 percent to USD 1.38 and exceeded the consensus estimate by 25.50 percent.

GAAP earnings per share for the second quarter reached USD 0.77, up 11.60 percent from USD 0.69 in the year-ago quarter. The result gives the upcoming October report a clear benchmark, especially because reported revenue growth remained restrained by the gastroenterology portfolio exits.

Guidance moves higher, risks remain

Zacks reported that CONMED lifted its full-year 2026 adjusted earnings guidance to USD 4.48-4.60 per share from USD 4.30-4.45. Reported revenue guidance stands at USD 1,358 million-1,373 million, compared with the previous USD 1,350 million-1,375 million range.

The operating picture is mixed by segment. Orthopedic Surgery revenue increased 8.20 percent year over year to USD 152.30 million in the second quarter, while General Surgery revenue fell 5.20 percent to USD 191.20 million; on an organic constant-currency basis, General Surgery revenue increased 5.30 percent.

The revised outlook also incorporates higher interest expenses and a higher tax-rate assumption, according to Zacks. That makes the October results important for testing whether stronger adjusted earnings can offset portfolio-related revenue pressure.

October results set the next test

Business Wire identifies CONMED as a medical technology company listed on the NYSE under CNMD and schedules the third-quarter release for October 28, 2026. Management is set to discuss the figures during a conference call at 4:30 p.m. ET the same day.

Pre-market price and stock facts

CONMED stock was trading at EUR 41.30 at Lang & Schwarz on October 5, 2026 at 7:59 a.m. CEST, with a plus 0.24 percent change versus the Lang & Schwarz prior close of EUR 41.20. The primary NYSE listing was last at USD 46.32 on October 2, 2026 at 4:00 p.m. ET, against a USD 31.44-53.66 52-week range.